The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

Ozcelik, M.; Odabas, H.; Ercelep, O.; Yuksel, S.; Mert, A.; Aydin, D.; Surmeli, H.; Isik, D.; Isik, S.; Oyman, A.; Ustaalioglu, B.; Aliustaoglu, M.; Gumus, M.

doi:10.1007/s12094-015-1408-6

The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

Ozcelik M., Odabas H., Ercelep O., Yuksel S., Mert A. G., Aydin D., ...Daha Fazla

CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.18, sa.6, ss.617-624, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18 Sayı: 6
Basım Tarihi: 2016
Doi Numarası: 10.1007/s12094-015-1408-6
Dergi Adı: CLINICAL & TRANSLATIONAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.617-624
Bezmiâlem Vakıf Üniversitesi Adresli: Evet

Özet

The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to evaluate the activity of bevacizumab plus capecitabine combination in elderly mCRC patients who were not suitable for chemotherapy with irinotecan and oxaliplatin-containing regimens.